Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

PURPOSE: Angiogenesis plays a pivotal role in tumor growth and metastasis. Sorafenib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), combined with bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF-A), would vertically inhibit VEGF/VEG...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: Falchook, Gerald S., Wheler, Jennifer J., Naing, Aung, Piha-Paul, Sarina A., Fu, Siqing, Tsimberidou, Apostolia M., Hong, David S., Janku, Filip, Zinner, Ralph, Jiang, Yunfang, Huang, Mei, Lin, Quan, Parkhurst, Kristin, Kurzrock, Razelle
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477529/
https://ncbi.nlm.nih.gov/pubmed/25363205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0176-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items